Drug Profile

NYPRG 101

Alternative Names: BOL-148; NYPRG-101

Latest Information Update: 05 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ceruvia Lifesciences
Class Analgesics; Antidepressants; Antimigraines; Antipsychotics; Drug withdrawal therapies; Ergolines; Ergot alkaloids; Neuropsychotherapeutics; Small molecules
Mechanism of Action Serotonin 5-HT2A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

05 Sep 2023 Phase-I clinical trials in Alcoholism in USA (unspecified route) (Ceruvia Lifesciences pipeline; September 2023)
05 Sep 2023 Phase-I clinical trials in Opioid-related disorders in USA (unspecified route) (Ceruvia Lifesciences pipeline; September 2023)
24 May 2023 Chemical structure information added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com